Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan
Heather Moore(Duke University Hospital), Kelly Westbrook(Duke Medical Center), Amy Guisinger(Duke University Hospital), Jeremy Force(Daiichi Sankyo (Germany)), Scott Shofer(Cancer Institute (WIA)), Sarah Sammons(Dana-Farber Cancer Institute), Gloria Broadwater, Carey K. Anders(Duke University)
Cited by 4
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
|Clinical Breast Cancer|2009|644